Although relatively rare, shared neoantigens arise from recurrent mutations in tumor driver genes such as KRAS, tumor suppressor genes such as TP53, and viral oncogenes such as HPV-derived E6 and E7. This evidence concerns the gene KRAS and neoplasm.